Lu AF28996
| Clinical data | |
|---|---|
| Other names | Lu-AF28996; LuAF28996; Lu-AF-28996 |
| Routes of administration | Oral[1] |
| Drug class | Dopamine receptor agonist; Dopamine D1 and D2 receptor agonist |
Lu AF28996 is a dual dopamine D1 and D2 receptor agonist which is under development for the treatment of Parkinson's disease.[1][2][3][4][5][6] It is taken orally.[1] Lu AF28996 was first described in the scientific literature by 2021.[3] It is under development by Lundbeck.[1][2] As of April 2025, the drug is in phase 1 clinical trials.[1][2] The chemical structure of Lu AF28996 does not yet appear to have been disclosed.[1]
See also
References
- ^ a b c d e f "Lu AF 28996". AdisInsight. 28 April 2025. Retrieved 28 January 2026.
- ^ a b c "Delving into the Latest Updates on Lu-AF28996 with Synapse". Synapse. 3 December 2025. Retrieved 28 January 2026.
- ^ a b McFarthing K, Rafaloff G, Baptista MA, Wyse RK, Stott SR (2021). "Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update". Journal of Parkinson's Disease. 11 (3): 891–903. doi:10.3233/JPD-219006. PMC 8461678. PMID 34151864.
- ^ Isaacson SH, Hauser RA, Pahwa R, Gray D, Duvvuri S (2023). "Dopamine agonists in Parkinson's disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment". Clinical Parkinsonism & Related Disorders. 9 100212. doi:10.1016/j.prdoa.2023.100212. PMC 10366643. PMID 37497384.
- ^ McFarthing K, Buff S, Rafaloff G, Pitzer K, Fiske B, Navangul A, et al. (2024). "Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2024 Update". Journal of Parkinson's Disease. 14 (5): 899–912. doi:10.3233/JPD-240272. PMC 11307066. PMID 39031388.
- ^ Gros P, Garcia LA, Fox SH (May 2025). "Experimental Therapeutics in Parkinson's Disease: A Review". Neurologic Clinics. 43 (2): 399–426. doi:10.1016/j.ncl.2024.12.013. PMID 40185528.